Parkinson’s Disease Psychosis Market

Market Overview:

The 7 major Parkinson’s disease psychosis markets reached a value of US$ 513.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 676.6 Million by 2034, exhibiting a growth rate (CAGR) of 2.55% during 2024-2034.

The Parkinson’s disease psychosis market has been comprehensively analyzed in IMARC's new report titled "Parkinson’s Disease Psychosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Parkinson's disease psychosis (PDP) refers to a debilitating condition that can affect individuals suffering from Parkinson's disease. While Parkinson's primarily involves motor signs like tremors and rigidity due to the loss of dopamine-producing cells in the brain, PDP introduces a layer of non-motor symptoms. These can include hallucinations, delusions, and disorganized thinking. Hallucinations often involve seeing, hearing, or feeling things that aren't actually present, while delusions entail holding false beliefs despite evidence to the contrary. These symptoms can greatly impact a patient's quality of life, leading to increased caregiver burden and functional impairment. The diagnosis of PDP involves careful evaluation by medical professionals. It's essential to differentiate these symptoms from other potential causes, such as medication side effects, infections, or various other psychiatric conditions. A comprehensive medical history, neurological examination, and sometimes neuropsychological assessments are utilized to determine the presence and severity of the underlying indications.

The increasing prevalence of neurochemical changes, causing disruption of neurotransmitter systems in the brain, is primarily driving the Parkinson's disease psychosis market. In addition to this, the inflating utilization of antipsychotic drugs like pimavanserin, specifically tailored for PDP, is also creating a positive outlook for the market. These medications work by modulating serotonin receptors to alleviate hallucinations and delusions without exacerbating motor symptoms, thereby enriching the quality of life for individuals suffering from the ailment. Moreover, the widespread adoption of non-pharmacological interventions, including cognitive-behavioral therapy and caregiver education, which help in managing behavioral changes and promoting better-coping mechanisms for patients and their families, is further bolstering the market growth. Apart from this, the rising application of gene therapy, since it aims to correct or replace the underlying genetic irregularities contributing to Parkinson's and its associated psychosis, is acting as another significant growth-inducing factor. Additionally, the growing awareness of PDP among healthcare professionals and caregivers, that can facilitate early detection and intervention to enable timely and appropriate management is also augmenting the market growth. Furthermore, the escalating usage of deep brain stimulation (DBS) techniques, which involve the implantation of electrodes to modulate neural activity and reduce symptoms, is expected to drive the Parkinson's disease psychosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Parkinson’s disease psychosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Parkinson’s disease psychosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Parkinson’s disease psychosis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Parkinson’s disease psychosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Parkinson’s disease psychosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Parkinson’s disease psychosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Parkinson’s disease psychosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Parkinson’s disease psychosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Parkinson’s disease psychosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Parkinson’s disease psychosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Parkinson’s disease psychosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Parkinson’s disease psychosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Parkinson’s disease psychosis across the seven major markets?
• What is the size of the Parkinson’s disease psychosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Parkinson’s disease psychosis?
• What will be the growth rate of patients across the seven major markets?
   

Parkinson’s Disease Psychosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Parkinson’s disease psychosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Parkinson’s disease psychosis market?
• What are the key regulatory events related to the Parkinson’s disease psychosis market?
• What is the structure of clinical trial landscape by status related to the Parkinson’s disease psychosis market?
• What is the structure of clinical trial landscape by phase related to the Parkinson’s disease psychosis market?
• What is the structure of clinical trial landscape by route of administration related to the Parkinson’s disease psychosis market?